若生智能
Drug Database
CH

chlormadinone acetate + ethinyl estradiol (Balianca / Belara / CG5025)

✓ Approved

Faes · AR · 小分子

什么是 chlormadinone acetate + ethinyl estradiol？

chlormadinone acetate + ethinyl estradiol 是一种小分子，由Faes研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Balianca, Belara, CG5025
公司Faes
药物类别小分子
分子靶点AR, ESR1
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Faes

作用机制

分子靶点

chlormadinone acetate + ethinyl estradiol 作用于 2 个分子靶点：

ARandrogen receptor (TFM, NR3C4)
ESR1estrogen receptor 1 (ESR, ESTRR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

chlormadinone acetate + ethinyl estradiol 针对 2 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Reproductive system and breast disordersPolycystic ovaries✓ Approved
Endocrine disordersPolycystic ovarian syndrome✓ Approved

相关研究文献

PubMedCarbohydrate polymers2026-06-13

Correlating polymer solution and membrane fabrication with morphological and permeation properties of cellulose acetate ultrafiltration membranes.

Pires Rita F RF, Valente Margarida P MP, Rodrigues Flávia S C FSC, Charas Ana A et al.

Cellulose acetate (CA) membranes were prepared by phase inversion using three fixed solvent compositions (30/53, 31/52 and 35/48 wt% of formamide/acetone) while varying the air exposure time prior to immersion (0, 10, and 30 s). The influence of the percentage of formamide and evaporation time on the membrane structure and performance was investigated through scanning electron microscopy (SEM) and atomic force microscopy (AFM) characterization, pure water permeation, and molecular weight cut-off (MWCO) measurements. Results demonstrated that evaporation time was a key factor in controlling the membrane morphology. Short evaporation times favored fast demixing and the formation of macrovoids, while longer evaporation times (30 s) suppressed these defects and produced smoother selective layers. The CA(35)-30 membrane exhibited the most favorable properties, including a water permeability of 36.0 L/h/m2/bar, an MWCO of 35.0 kDa, low surface roughness (RMS = 1.81 nm), and an asymmetric structure free of macrovoids and surface stripes.

PMID 42285671
阅读全文 →
PubMedJournal of environmental management2026-06-13

Development of membrane bioreactor using biopolymer recovered from corncob waste for tannery wastewater treatment.

Udayakumar Sathya S, Prabhu S Melvin SM, Minnalkodi Senguttuvan Keerthana Rani KR

This study presents the novel development and application of a cellulose acetate membrane synthesized from corncob waste, an agrowaste, in a submerged membrane bioreactor (MBR) system for treating real tannery wastewater. Corncob-derived cellulose biomaterial was used to fabricate the hollowfibre membranes for the very first time. Phase inversion method was used with N-methyl-2-pyrrolidone (NMP) as solvent and polyvinylpyrrolidone (PVP) as the pore-forming additive. Fourier Transform Infrared Spectroscopy (FTIR) confirmed successful acetylation with characteristic ester peaks at 1736 cm-1, along with key cellulose backbone features. The membrane was integrated into a lab-scale aerobic MBR treating real tannery wastewater with an average feed COD of 2550 mg/L, TSS of 1080 mg/L, NH4+-N of 162 mg/L, and TDS of 7440 mg/L. COD value decreased up to 856 mg/L during biological degradation process and the permeate had the average COD value of 640 mg/L, achieving overall removal efficiency of 75%. Initially, NH4+-N during acclimation process had dropped up to 141 mg/L and then finally reached the value of 55 mg/L. Membrane flux declined steadily from 26.18 to 3.89 L/m2·h as mixed liquor suspended solids (MLSS) increased from 8000 to 12,000 mg/L. The flux recovery ratio (FRR) after chemical cleaning with 0.5% NaOCl was 49.94% for the cellulose acetate membrane and 74.98% for the PVDF membrane, suggesting that further surface modifications or pretreatment steps may be necessary to enhance antifouling properties of biopolymer-based membranes. To improve the final effluent quality, ozonation was applied to the permeate for 60 min. This advanced oxidation step further reduced COD from 640 mg/L to 220 mg/L and significantly removed residual colour.

PMID 42284846
阅读全文 →
PubMedCommunications chemistry2026-06-13

Selective cellulose fibril release from hardwoods libriform tissue.

von Usslar Felicitas F, Günaydın Büşra Ece BE, Zollfrank Cordt C

Cellulose fibrils are a renewable and biodegradable resource, but their extraction typically requires complete destruction of the original wooden matrix. We present a targeted strategy that enables selective liberation of cellulose microfibrils while preserving the integrity of the surrounding native wood structure. By combining partial delignification with localized surface modification using the ionic liquid 1-butyl-3-methylimidazolium acetate ([Bmim][OAc]), we enable selective liberation and separation of cellulose microfibrils without bulk dissolution or structural damage. This spatially confined treatment exploits the intrinsic anisotropy of the native cellulose architecture, allowing controlled fibril release while maintaining the original orientation and structural framework. These findings reveal how precise chemical interventions can expand the toolbox of cellulose chemistry and unlock new opportunities for advanced wood-based material engineering.

PMID 42286238
阅读全文 →
PubMedProstate cancer and prostatic diseases2026-06-13

Association between concomitant ACEI/ARBs use and survival of patients with prostate cancer receiving abiraterone acetate: A post-hoc analysis of two randomized trials.

Zhao Junliang J, Cai Xinyang X, Mo Zijun Z, Zhao Diwei D et al.

Cardiovascular disease (CVD) is the leading cause of non-cancer mortality in prostate cancer (PCa) patients. The management of CVD, including hypertension, holds equal significance to cancer treatment. However, the optimal antihypertensive agent for blood pressure management in PCa patients receiving abiraterone acetate (AA) is still unclear. This study aims to investigate the association between various antihypertensive regimens and survival outcomes in PCa patients treated with AA. We performed a post-hoc observational analysis using data from COU-AA-301 and COU-AA-302. Radiographic progression-free survival (rPFS), overall survival (OS) and prostate cancer-specific survival (PCSS) were evaluated using the Kaplan-Meier method. Cox proportional hazards models were used to obtain hazard ratios (HRs) and associated 95% confidence intervals (CIs). Among the AA groups of COU-AA-301 and COU-AA-302, angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) monotherapy was associated with longer rPFS (HR 0.82, 95% CI 0.59-1.13; HR 0.71, 95% CI 0.53-0.95), OS (HR 0.66, 95% CI 0.41-1.06; HR 0.70, 95% CI 0.53-0.92) and PCSS (HR 0.72, 95% CI 0.44-1.19; HR 0.67, 95% CI 0.49-0.92). Multiple-class antihypertensive treatment regimens including ACEI/ARBs were associated with longer rPFS (HR 0.74, 95% CI 0.59-0.92; HR 0.71, 95% CI 0.54-0.94), OS (HR 0.76, 95% CI 0.57-1.01; HR 0.72, 95% CI 0.55-0.94) and PCSS (HR 0.71, 95% CI 0.51-0.99; HR 0.62, 95% CI 0.46-0.83). Multivariable analysis indicated that ACEI/ARBs were associated with improved rPFS (HR 0.72, 95% CI 0.60-0.86; HR 0.75, 95% CI 0.60-0.94), OS (HR 0.71, 95% CI 0.56-0.91; HR 0.70, 95% CI 0.56-0.88) and PCSS (HR 0.73, 95% CI 0.55-0.96; HR 0.64, 95% CI 0.50-0.82). In this post-hoc analysis, concomitant use of ACEI/ARBs was associated with longer rPFS, OS and PCSS in PCa patients treated with AA. The potential role of ACEI/ARB-containing antihypertensive regimens in these patients warrants further investigation. ClinicalTrials.gov Identifier: NCT00638690, NCT00887198.

PMID 42286315
阅读全文 →
PubMedChinese journal of natural medicines2026-06-13

Quzhou Fructus Aurantii extract alleviates metabolic dysfunction-associated steatohepatitis by activating the PPARα signaling pathway.

Wu Lianhao L, Zhu Wenwen W, Zhang Shuohan S, Chen Ranran R et al.

Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic metabolic disease that severely affects human health. Quzhou Fructus Aurantii ethyl acetate extract (QFAEE) is a mixture rich in diverse natural flavonoids that exhibits multiple pharmacological properties, including significant anti-inflammatory and antioxidant activities. However, the anti-MASH effects of QFAEE and the underlying mechanisms remain unknown. This study aimed to investigate the therapeutic effects of QFAEE on MASH and the related mechanisms. The therapeutic effects of QFAEE on hepatic steatosis, inflammatory responses, oxidative stress and apoptotic activity were systematically evaluated in both in vivo and in vitro models of metabolic stress. QFAEE administration significantly reduced hepatic lipid accumulation, inflammatory cell infiltration and liver injury in HFHC diet-fed mice. Combined RNA sequencing and network pharmacology analyses revealed that QFAEE exerted its anti-MASH effects through modulation of the PPAR signaling pathway. QFAEE ameliorated MASH by activating PPARα and subsequently upregulating CPT1A, which promoted mitochondrial and peroxisomal β-oxidation. Notably, PPARα inhibition promoted hepatic lipid accumulation, inflammation and oxidative stress in hepatocytes, all of which were significantly attenuated by QFAEE treatment. These findings suggest that QFAEE prevents metabolic stress-induced MASH progression by activating PPARα signaling.

PMID 42285690
阅读全文 →
PubMedMaturitas2026-06-13

Neurokinin pathway botanical antagonist for menopausal vasomotor symptoms: A randomized, double-blind, placebo-controlled study.

Lederman Samuel S, Minkin Mary Jane MJ, Doyle Audra Lisa AL, Rubio Jevaneeh J et al.

Vasomotor symptoms (VMS) are a prevalent and disruptive manifestation of menopause, and many women prefer nonhormonal, nonpharmacologic treatment options. This study evaluated the efficacy of a patented multi-ingredient botanical neurokinin inhibitor (BNI) on VMS and other patient-reported outcome measures. A randomized, double-blind, placebo-controlled trial was performed in menopausal women with 5 or more moderate to severe hot flashes daily. Participants were enrolled from community medical practices in the United States and randomized to BNI or placebo for 12 weeks. BNI is a novel formulation of plant extracts that attenuates neurokinin receptor signaling in vivo. Primary endpoints were changes in daily VMS frequency and score on the Hot Flash Related Daily Interference Scale (HFRDIS). Secondary endpoints included changes in Menopause-Specific Quality of Life (MENQOL) and Pittsburgh Sleep Quality Index (PSQI). Serum estrogen and liver function were assessed in a subgroup of patients. Of 74 randomized participants, 68 completed the trial (BNI, n = 32; placebo, n = 36). BNI supplementation reduced VMS frequency by 2.2 hot flashes per day more than placebo (p = 0.003), corresponding to a 47.7% relative decrease. HFRDIS was improved in the BNI group (p = 0.037), with significant reduction on all subscales. No significant differences were observed in global menopause symptoms (MENQOL) or sleep quality (PSQI). No changes in serum estradiol or liver function abnormalities were detected. BNI was well tolerated, with no difference in adverse events between groups. A combination of botanically derived neurokinin inhibitors produces significant and sustained relief of vasomotor symptoms in menopausal women. gov registration: NCT05813067.

PMID 42284819
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多chlormadinone acetate + ethinyl estradiol